Avsnitt
-
ACC Part 2: The TACT2 trial of chelation, inter-atrial shunts for HF, and triglyceride lowering; plus diltiazem and Factor Xa anticoagulants are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. TACT 2
Chelation Therapy Provides No Benefit Post-MI
https://www.medscape.com/viewarticle/chelation-therapy-provides-no-benefit-post-mi-2024a10006l5
Chelation Therapy and CV Risk: Why TACT2 Showed No Benefit https://www.medscape.com/viewarticle/chelation-therapy-and-cv-risk-why-tact2-showed-no-benefit-2024a1000761?src=
JAMA TACT 1 paper https://jamanetwork.com/journals/jama/fullarticle/1672238 Diabetes Subgroup paper https://pubmed.ncbi.nlm.nih.gov/24254885/ A New Look at P-values https://evidence.nejm.org/doi/abs/10.1056/EVIDoa2300003 PARAGON HF https://www.nejm.org/doi/full/10.1056/NEJMoa1908655II. Interatrial Shunts for HF
No Net HF Benefit for Interarterial Shunt Device
https://www.medscape.com/viewarticle/no-net-hf-benefit-interarterial-shunt-device-2024a10006kk
REDUCE LAP HF II https://doi.org/10.1016/S0140-6736(22)00016-2III. Triglyceride Lowering
Early Olezarsen Results Show 50% Reduction in Triglycerides
https://www.medscape.com/viewarticle/early-olezarsen-results-show-50-reduction-triglycerides-2024a10006oz
Is It Time to Stop Treating High Triglycerides?
https://www.medscape.com/viewarticle/990126
NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2402309Substantial Triglyceride Reduction With Plozasiran
https://www.medscape.com/viewarticle/substantial-triglyceride-reduction-plozasiran-2024a10006wf?icd=login_success_email_match_norm
JAMA Cardiology https://jamanetwork.com/journals/jamacardiology/article-abstract/2817469IV. Diltiazem and Factor Xa inhibitors
JAMA Vanderbilt University Paper https://jamanetwork.com/journals/jama/fullarticle/2817546You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
ACC Recap #1: DanGer Shock (plus a sobering JAMA research letter on Impella use), REDUCE-AMI, PREVENT, and EMPACT-MI are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DanGer-Shock Trial
Impella CP Improves Survival in STEMI, Cardiogenic Shock https://www.medscape.com/viewarticle/impella-cp-improves-survival-stemi-cardiogenic-shock-2024a10006kz
Impella Saves Lives in Cardiogenic Shock, but Patient Selection Key https://www.medscape.com/viewarticle/1000659
Published DanGer Shock Study https://www.nejm.org/doi/full/10.1056/NEJMoa2312572 JAMA Research letter https://jamanetwork.com/journals/jama/article-abstract/2817457II. REDUCE-AMI Trial
New Data Question Beta-Blockers Post-MI With Preserved EF https://www.medscape.com/viewarticle/new-data-question-beta-blockers-post-mi-preserved-ef-2024a10006y8
Beta-Blockers Post-MI Past Their Expiration Date: REDUCE-AMI https://www.medscape.com/viewarticle/1000663
REDUCE-AMI paper https://www.nejm.org/doi/full/10.1056/NEJMoa2401479 Meta-analysis: Beta Blockers for MI https://doi.org/10.1016/j.amjmed.2014.05.032III. PREVENT Trial
Preventive PCI for Vulnerable Plaques Reduces Cardiac Events
https://www.medscape.com/viewarticle/preventive-pci-vulnerable-plaques-reduces-cardiac-events-2024a10006tc
Preventive Coronary Stents: Not There Yet
https://www.medscape.com/viewarticle/preventive-coronary-stents-not-there-yet-2024a10006yr
PREVENT https://doi.org/10.1016/S0140-6736(24)00413-6IV. EMPACT MI trial of Empagliflozin in the Post-MI setting
Empagliflozin Fails to Reduce Events After Acute MI
https://www.medscape.com/viewarticle/empagliflozin-fails-reduce-events-after-acute-mi-2024a10006kn
EMPACT-MI: Another SGLT2 Inhibitor Miss in Post-MI Care https://www.medscape.com/viewarticle/1000684 EMPACT MI https://www.nejm.org/doi/10.1056/NEJMoa2314051 DAPA MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286 PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508 Kaul thread https://x.com/kaulcsmc/status/1776611935842165029 Kaul paper https://www.ahajournals.org/doi/full/10.1161/circulationaha.116.022537You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Saknas det avsnitt?
-
Statins and diabetes, AAD in patients with heart disease, tricuspid valve interventions, and an ACC preview are the topics John Mandrola, MD, discusses in this week’s podcast.This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Statins and Diabetes
Meta-analysis in Lancet-Diabetes https://doi.org/10.1016/S2213-8587(24)00040-8 Editorial https://doi.org/10.1016/S2213-8587(24)00059-7 NEJM Paper on Gene Variants and DM https://www.nejm.org/doi/full/10.1056/nejmoa1604304 JAMA Paper on Gene Variants and DM https://jamanetwork.com/journals/jama/fullarticle/2565289II. Anti-arrhythmic Drugs in Patients With Serious Heart Disease
UPenn Paper on AADs for PVC Suppression https://doi.org/10.1016/j.jacep.2024.01.021 Three Questions for Evidence-Based Cardiac EP https://www.ahajournals.org/doi/full/10.1161/circoutcomes.110.957381 CAST trial https://www.nejm.org/doi/full/10.1056/NEJM199103213241201III. Tricuspid Valve Interventions
FDA Clears TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-clears-triclip-tricuspid-regurgitation-2024a100068o
FDA Panel in Favor of TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n
Slides for Trisend II TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525IV. ACC Preview
Mandrola's Three Trials to Look for at the 2024 American College of Cardiology Scientific Sessions
https://www.medscape.com/viewarticle/1000613
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Intermittent fasting, anticoagulation decisions, heterogenous treatment effects, frailty in HF, the importance of the ECG, and industry conflicts are the topics John Mandrola, MD, covers this week.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Intermittent Fasting
No, Intermittent Fasting Won't Kill You
https://www.medscape.com/viewarticle/1000544
NEJM Paper on Time-Restricted Eating https://www.nejm.org/doi/full/10.1056/NEJMoa2114833 JAMA TREAT Clinical Trial https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2771095II. Stroke Prevention with OAC
Shah Meta analysis of Vitamin K Agonists in AF https://www.ahajournals.org/doi/abs/10.1161/CIRCOUTCOMES.123.010269III. Heterogenous Treatment Effects in Trials
Pivotal CV Trials May Not Apply to Complex Patients
https://www.medscape.com/viewarticle/989129
Analysis of 8 Trials of Multimorbidity and Treatment Response https://doi.org/10.1016/j.amjmed.2024.01.028IV. Frailty and HF
Circulation Outcomes: Multidomain Frailty and Mode of Death in HF https://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010416V. ECG in LBBB
JAMA Cardiology: Revised Definition of LBBB https://jamanetwork.com/journals/jamacardiology/fullarticle/2816973VI. Industry Payments to Doctors
JAMA: Payments to US Physicians by Specialty https://jamanetwork.com/journals/jama/fullarticle/2816900You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
p>Obesity drugs as ASCVD-modifiers, HR monitors, when journals publish obvious facts, and effect scores and sorting out signals from RCTs are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Denmark Notes
II. FDA approval of Semaglutide
FDA Approves Semaglutide for Cardiovascular Risk Reduction
https://www.medscape.com/viewarticle/fda-approves-semaglutide-cardiovascular-risk-reduction-2024a10004ix
Select TrialIII. PPG Monitor Accuracy
Research Letter https://doi.org/10.1016/j.jacc.2024.01.024IV. AAD and Bradycardia
Anti-arrhythmic Drugs Linked to Bradycardia in Patients With AF
https://www.medscape.com/viewarticle/anti-arrhythmic-drugs-linked-bradycardia-patients-af-2024a10004vw
JACC paper on AAD Adverse Effects https://doi.org/10.1016/j.jacc.2024.01.013V. Finding Signals in RCTs
JAMA paper on Treatment Effects of Oxygen Targets DANISH trial https://www.nejm.org/doi/full/10.1056/nejmoa1608029 LAFFLIN et al. Scoring System to Assess Generalizability of Trial Results https://doi.org/10.1177/2047487318815967
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Plastics and heart disease, MINT trial letters-to-the-editor and Bayes theorem, and Brugada syndrome are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Plastics and Heart Disease
Plastic Particles in Carotid Plaques Linked to CV Events
https://www.medscape.com/viewarticle/plastic-particles-carotid-plaques-linked-cv-events-2024a10004ge
Plastics and ASCVD Study https://www.nejm.org/doi/full/10.1056/NEJMoa2309822 Review https://www.nejm.org/doi/full/10.1056/NEJMra2300476 Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2400683II. MINT trial LTE and Bayes Theorem
In MI With Anemia, Results May Favor Liberal Transfusion: MINT https://www.medscape.com/viewarticle/998376
The MINT Study https://www.nejm.org/doi/full/10.1056/NEJMoa2307983 Letter-to-the-Editor https://www.nejm.org/doi/full/10.1056/NEJMc2400982 Likelihood Ratio https://www.cebm.ox.ac.uk/resources/ebm-tools/likelihood-ratiosIII. Brugada Syndrome
The EHJ paper: https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehae133/7623123You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
The Western AF meeting, aspirin, cannabis use, LVEF in athletes, and shared decision making before ICD implantation are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. ASA in Primary Prevention
Campbell Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.065420 Swedish Observational study https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.117.028321 ASPREE https://www.nejm.org/doi/full/10.1056/NEJMoa1805819II. Cannabis
Cannabis Use Tied to Increased Cardiovascular Risk
https://www.medscape.com/viewarticle/cannabis-use-tied-increased-cardiovascular-risk-2024a10003yr
It Sure Looks Like Cannabis Is Bad for the Heart, Doesn’t It?
https://www.medscape.com/viewarticle/1000250
Journal of the AHA Observational Study https://www.ahajournals.org/doi/full/10.1161/JAHA.123.030178III. Low EF in Athletes
Reduced Ejection Fraction in Elite Endurance Athletes: Clinical and Genetic Overlap With Dilated Cardiomyopathy https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.063777IV. ICDs and Shared Decision-Making
Association of a Medicare Mandate for Shared Decision-Making With Cardiac Device Utilization https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2815017You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Reading incidental CAC on chest CT scans, exercise benefits in women vs men, PCI with or without imaging, and trial non-reporting are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Incidental CAC on Chest CT
Incidental CAC Tweet When Does a Calcium Score Equate to Secondary Prevention?: Insights From the Multinational CONFIRM Registry https://doi.org/10.1016/j.jcmg.2023.03.008II. Exercise
Health Gains of Exercise Greater in Women?
https://www.medscape.com/viewarticle/health-gains-exercise-greater-women-2024a10003fv
Sex Differences in Association of Physical Activity With All-Cause and Cardiovascular MortalityIII. PCI With or Without Imaging
Intravascular Imaging in PCI: Time for a Guideline Update?
https://www.medscape.com/viewarticle/995677
Meta-analysis paper Lancet https://doi.org/10.1016/S0140-6736(23)02454-6 Imaging uptake paper https://doi.org/10.1093/eurheartj/ehad430IV. Trial Non-reporting
The Ghost Research Haunting Nordic Medical Trials
https://www.medscape.com/viewarticle/ghost-research-haunting-nordic-medical-trials-2024a10003gz
Manuscript/preprint https://www.medrxiv.org/content/10.1101/2024.02.04.24301363v1#T10 Nissen (Rosiglitazone) https://www.nejm.org/doi/10.1056/NEJMoa072761You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
An update in trial interpretation, CI, and P-values; percutaneous tricuspid Interventions; and news on HDL and humility in Medicine are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Evidence of Absence Is not Absence of Evidence
Feb 09, 2024 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1000101
ARCADIA Trial https://jamanetwork.com/journals/jama/fullarticle/2814933 FOURIER Trial https://www.nejm.org/doi/full/10.1056/nejmoa1615664 Sample Size Calculator https://clincalc.com/stats/samplesize.aspxII. Tricuspid Valve Interventions
FDA OKs First Transcatheter Tricuspid Valve Replacement
https://www.medscape.com/viewarticle/fda-oks-first-transcatheter-tricuspid-valve-replacement-2024a10002dq
FDA Panel in Favor of TriClip for Tricuspid Regurgitation
https://www.medscape.com/viewarticle/fda-panel-favor-triclip-tricuspid-regurgitation-2024a100037n
Cardiothoracic Surgical Trials Network Study https://www.nejm.org/doi/full/10.1056/NEJMoa2115961 TRILUMINATE https://www.nejm.org/doi/full/10.1056/NEJMoa2300525 KAUL Tweet on ATTR Cardiomyopathy https://twitter.com/kaulcsmc/status/1753552603534016622?s=20 APOLLO B trial https://www.nejm.org/doi/full/10.1056/NEJMoa2300757 Al-Lamee Tweet on Sham Controls https://x.com/rallamee/status/1758236588570562736III. HDL Cholesterol
Rationale paper — AEGIS https://doi.org/10.1016/j.ahj.2020.10.052 Press Release AEGIS II https://www.prnewswire.com/news-releases/csl-announces-top-line-results-from-the-phase-3-aegis-ii-trial-evaluating-the-efficacy-and-safety-of-csl112-apolipoprotein-a-i-human-302059156.htmlYou may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Beta-blocker withdrawal in HFpEF, the ARCADIA trial, food as medicine, and bariatric surgery are the topics John Mandrola, MD, discusses in today’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. HFpEF and Heart Rate
PRESERVE HF Substudy https://jamanetwork.com/journals/jamacardiology/fullarticle/2814596 PRESERVE HF Original https://doi.org/10.1016/j.jacc.2021.08.073II. ARCADIA trial
ARCADIA Main Paper: Apixaban vs ASA https://jamanetwork.com/journals/jama/fullarticle/2814933 KAMEL’s AF and Stroke Paper 10.1161/STROKEAHA.115.012004 AVERROES Substudy -- 10.1016/S1474-4422(12)70017-0III. Food as Medicine
Food-As-Medicine Trial results: https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2812982 NPR Story https://www.npr.org/sections/thesalt/2017/05/08/526952657/fresh-food-by-prescription-this-health-care-firm-is-trimming-costs-and-waistlineIV. Bariatric Surgery
Weight Loss Surgery Yields Long-Term BP Control in Obesity
https://www.medscape.com/viewarticle/weight-loss-surgery-yields-long-term-bp-control-obesity-2024a10002le
Gateway RCT https://doi.org/10.1016/j.jacc.2023.11.032You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
FDA approves PFA for AF ablation, flawed comparisons of TEER vs MV surgery and PCI vs CABG, and cardiologists struggling with board exams are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. PFA
FDA Okays Boston Scientific PFA System for Paroxysmal AF
https://www.medscape.com/viewarticle/fda-okays-boston-scientific-pfa-system-paroxysmal-af-2024a1000275
Pulsed-Field Ablation for AF: The Promise and the Reality
https://www.medscape.com/viewarticle/995675
ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291 EU-PORIA Registry https://doi.org/10.1093/europace/euad185 Tomlinson/Mandrola Editorial https://www.jacc.org/doi/10.1016/j.jacc.2020.07.032II. TEER vs MV Surgery
EHJ Paper https://doi.org/10.1093/eurheartj/ehae046III. ISCHEMIA Post-Hoc Studies
JACC Post-Hoc ISCHEMIA Trialhttps://doi.org/10.1016/j.jacc.2023.11.002 Main ISCHEMIA paper https://www.nejm.org/doi/full/10.1056/nejmoa1915922 FAME 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2112299IV. Board Exams
More Cardiologists Failing the Boards, Why and How to Fix?
https://www.medscape.com/viewarticle/more-cardiologists-failing-boards-why-and-how-fix-2024a10001oi
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
LAAO, more evidence that stable CAD is stable, CRT benefit over the long-term, and AF monitoring after stroke are the topics John Mandrola, MD, covers in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. LAAO
This Week in Cardiology Podcast, Dec 15, 2023 https://www.medscape.com/viewarticle/999282
European Heart Journal paper https://academic.oup.com/eurheartj/article/45/3/214/7471675 LAAOS 3 https://www.nejm.org/doi/full/10.1056/NEJMoa2101897II. CAD after Transcatheter Aortic Valve Implantation
Cleveland Clinic Observational study https://doi.org/10.1093/eurheartj/ehae019 ACTIVATION trial https://doi.org/10.1016/j.jcin.2021.06.041III. Cardiac Resynchronization Therapy
Original RAFT 2010 https://www.nejm.org/doi/full/10.1056/nejmoa1009540 Long-term RAFT https://www.nejm.org/doi/full/10.1056/NEJMoa2304542 Editorial https://www.nejm.org/doi/full/10.1056/NEJMe2312419IV. AF Monitoring After Stroke
Japanese Observational Study https://www.ahajournals.org/doi/10.1161/JAHA.123.031508 ARTESIA https://www.nejm.org/doi/full/10.1056/NEJMoa2310234 NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062 LOOP substudy https://jamanetwork.com/journals/jamaneurology/fullarticle/2795865 CRYSTAL AF https://www.nejm.org/doi/full/10.1056/nejmoa1313600You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Listener feedback on antiplatelet therapy after PCI, bempedoic acid, off-Label PFO Closure, and palliative care are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Listener Feedback on Antiplatelet Therapy After PCI
Long-term Clopidogrel Has Advantages After Coronary Stenting
https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8
Host Exam Study; Extended FU of Host-Exam https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.122.062770II. Bempedoic Acid
This Week in Cardiology July 7, 2023 https://www.medscape.com/viewarticle/994089
NEJM: Bempedoic Acid and CV Outcomes JAMA: Primary Prevention Analysis https://jamanetwork.com/journals/jama/fullarticle/2806646 JAMA-Cardiology: Total Events Analysis https://jamanetwork.com/journals/jamacardiology/fullarticle/2813647/III. Off-Label PFO Closure
Circulation Outcomes Paperhttps://www.ahajournals.org/doi/10.1161/CIRCOUTCOMES.123.010200IV. Palliative Care
JAMA: Palliative Care ConsultationYou may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
GLP-1s and BaroStim Neo revisited, a new drug for transthyretin amyloid CM, clopidogrel vs ASA years after PCI and stent, and statins are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. GLP-1s and Obesity, BaroStim Neo Revisited
FDA Expands Label for CVRx Barostim System in HF https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx
JAMA Cardiology Special Communication – BDP https://jamanetwork.com/journals/jamacardiology/fullarticle/2810726
II. ATTR Cardiomyopathy
ATTRibute-CM NEJM paper https://www.nejm.org/doi/full/10.1056/NEJMoa2305434
Circulation Review of TTR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.111.078915
ATTR-ACT (Tafadimis) https://www.nejm.org/doi/10.1056/NEJMoa1805689
III. Clopidogrel vs ASA Years After PCI
Long-term Clopidogrel Has Advantages After Coronary Stenting
https://www.medscape.com/viewarticle/long-term-clopidogrel-has-advantages-after-coronary-stenting-2024a10000c8
Stop DAPT Original Trial
STOP DAPT at 5 Years https://doi.org/10.1016/j.jacc.2023.10.013
Network Meta-analysis of P2Y12-I vs ASA https://doi.org/10.1016/j.jcin.2022.08.009
IV. Statin Use
Statin Use Remains Low for At-Risk Patients
https://www.medscape.com/viewarticle/999043
Annals of Internal Medicine Observational Study https://doi.org/10.7326/M23-1915
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Neuro-modulation in HF, private equity owned hospitals, HCM, SCD and ICD re-evaluated, and peer review are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Neuromodulation for HFrEF
FDA Expands Label for CVRx Barostim System in HF
https://www.medscape.com/viewarticle/fda-expands-label-cvrx-barostim-system-hf-2023a1000wsx
BeAT HF trial https://doi.org/10.1016/j.jacc.2020.05.015
II. Private Equity Takeover of US Hospitals
Hospital Adverse Events Rise After Private Equity Acquisition
https://www.medscape.com/viewarticle/hospital-adverse-events-rise-after-private-equity-2023a1000wya
Changes in Hospital Adverse Events and Patient Outcomes Associated With Private Equity Acquisition: https://jamanetwork.com/journals/jama/article-abstract/2813379
RSS audio: https://bi.medscape.com/pi/editorial/studio/audio/2024/core/999557.mp3
III. Hypertrophic Cardiomyopathy
Positive Topline Results for SEQUOIA-HCM Trial in OHCM
https://www.medscape.com/viewarticle/positive-topline-results-sequoia-hcm-trial-ohcm-2023a1000wu9
IV. The ICD gets a ReLook
Study to Examine Routine ICD Implantation Post Heart Attack
https://www.medscape.com/viewarticle/study-examine-routine-icd-implantation-post-heart-attack-2023a1000wmd
PROFID Site https://profid-project.eu/profid-ehra-trial/
Declining Risk of Sudden Death in Heart Failure https://www.nejm.org/doi/full/10.1056/NEJMoa1609758
V. Peer Review
Prevalence of Short Peer Reviews in 3 Leading General Medical Journals -- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2812883
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
FDA approves PFA, breakthrough in PAH, residual leaks after percutaneous LAAO, OAC in low to intermediate risk people are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. FDA Approves PFA
FDA Approves First Pulsed Field Ablation System for AF https://www.medscape.com/viewarticle/fda-approves-first-pulsed-field-ablation-system-af-2023a1000vit
- PULSED AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064329
- ADVENT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307291
- MANIFEST https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.064959
II. Pulmonary HTN
Positive Topline Data for Sotatercept in PAH: STELLAR
https://www.medscape.com/viewarticle/982407
- STELLAR https://www.nejm.org/doi/10.1056/NEJMoa2213558
- Editorial on STELLAR https://www.nejm.org/doi/full/10.1056/NEJMe2300324
III. Peri-Device Leaks
- Greek Meta-analysis https://doi.org/10.1093/eurheartj/ehad828
IV. Intermediate Risk AF – Norwegian Study
- Stroke and bleeding risk in atrial fibrillation with CHA2DS2-VASC risk score of one: the Norwegian AFNOR study AFNOR Study https://doi.org/10.1093/eurheartj/ehad659
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Three aspects of the recent AF guideline documents and a possible new treatment of POTS are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I AF Guidelines
ACC/AHA Issue Updated Atrial Fibrillation Guideline
https://www.medscape.com/viewarticle/998956
- Guideline doc: https://www.ahajournals.org/doi/10.1161/CIR.0000000000001193
- CASTLE AF https://www.nejm.org/doi/full/10.1056/nejmoa1707855
- Analysis of US Inpatient Sample https://bmccardiovascdisord.biomedcentral.com/articles/10.1186/1471-2261-14-73
- RAFT AF https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057095
- Beta Blockers in AF https://pubmed.ncbi.nlm.nih.gov/25193873/
Section 2 AF Guidelines – EARLY Rhythm Control Gets Emphasis
- STOP AF https://www.nejm.org/doi/full/10.1056/NEJMoa2029554
- EARLY AF https://www.nejm.org/doi/full/10.1056/nejmoa2029980
- EAST https://www.nejm.org/doi/full/10.1056/NEJMoa2019422
- Natural History of AF https://www.jacc.org/doi/abs/10.1016/j.jacc.2019.09.050
Section 3 AF Guidelines – Dubious Upgrade of percutaneous LAAC
- PROTECT and PREVAIL Meta-analysis 5-year https://doi.org/10.1016/j.jacc.2017.10.021
- PINNACLE FLX https://www.ahajournals.org/doi/full/10.1161/CIRCULATIONAHA.120.050117
II. Postural Orthostatic tachycardia Syndrome
Vagus Nerve Stimulation Promising In POTS
https://www.medscape.com/viewarticle/998913
- Stavrakis et al. Noninvasive VNS for POTS https://doi.org/10.1016/j.jacep.2023.10.015
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
More from AHA including SGLT2 inhibitors, blood transfusion after MI; cracks in the armor of Factor XI inhibitors; and renal denervation are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. DAPA MI
Potential Dapagliflozin Benefit Post-MI Is Not a 'Mandate'
https://www.medscape.com/s/viewarticle/998378
- NEJM Evidence: Dapagliflozin After MI https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300286
II. Blood Transfusion Strategy Post MI
In MI With Anemia, Results May Favor Liberal Transfusion: MINT
https://www.medscape.com/viewarticle/998376
- MINT NEJM -- https://www.nejm.org/doi/full/10.1056/NEJMoa2307983
- REALITY https://jamanetwork.com/journals/jama/fullarticle/2776201
- PROTECTED TAVR - https://www.nejm.org/doi/full/10.1056/NEJMoa2204961
III. FACTOR XI
Impressive Bleeding Profile With Factor XI Inhibitor in AF: AZALEA
https://www.medscape.com/viewarticle/998418
Asundexian Phase 3 AF Study Halted for Lack of Efficacy
https://www.medscape.com/viewarticle/998665
- Abelacimab for VTE https://www.nejm.org/doi/full/10.1056/NEJMoa2105872
IV. Renal Denervation
FDA Panel Split on Efficacy of Spyral Renal Denervation
https://www.medscape.com/viewarticle/995800
FDA OKs Symplicity Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998664
- SPYRAL HTN OFF MED -- https://doi.org/10.1016/S0140-6736(20)30554-7
- SPRYAL HTN On Meds (Pilot Lancet 2018 ) https://doi.org/10.1016/S0140-6736(18)30951-6
- SPRYAL HTN ON Meds (Expansion Pilot) https://doi.org/10.1016/j.jacc.2023.08.045
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
An AHA Recap: SELECT, ORBITA2, and ARTESIA are the trials John Mandrola, MD, reviews in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
American Heart Association 2023 on theHeart.org | Medscape Cardiology
https://www.medscape.com/viewcollection/37277
I. SELECT Trial
Semaglutide 'A New Pathway' to CVD Risk Reduction: SELECT
https://www.medscape.com/viewarticle/998373
Positive Results From SELECT Begins a New Era in Cardiology
https://www.medscape.com/viewarticle/998217
Is It Time for Cardiologists to Treat Obesity?
https://www.medscape.com/viewarticle/998391
- SELECT trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
- SUSTAIN 6 https://www.nejm.org/doi/full/10.1056/nejmoa1607141
II. ORBITA 2
Angioplasty Finally Proven Beneficial in Stable Angina: ORBITA-2
https://www.medscape.com/s/viewarticle/998375
ORBITA-2 Saves Interventional Cardiology and Challenges Current Guidance
https://www.medscape.com/viewarticle/998213
PCI, the Antianginal 'Pill': ORBITA-2 in Detail
https://www.medscape.com/viewarticle/997777
- ORBITA-2; NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2310610
- ORBITA 1 https://doi.org/10.1016/S0140-6736(17)32714-9
III. ARTESIA
Apixaban Cuts Stroke but Ups Bleeding in Subclinical AF: ARTESIA
https://www.medscape.com/viewarticle/998379
Sadly, ARTESIA Doesn't Answer a Common Question in Cardiology
https://www.medscape.com/viewarticle/998215
- NOAH https://www.nejm.org/doi/full/10.1056/NEJMoa2303062
- ARTESIA https://www.nejm.org/doi/10.1056/NEJMoa2310234
- AVERROES https://www.nejm.org/doi/full/10.1056/NEJMoa1007432
- McIntyre Meta-analysis https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.123.067512
- TRENDS https://www.ahajournals.org/doi/10.1161/circep.109.849638
- ASSERT https://doi.org/10.1093/eurheartj/ehx042
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
-
Renal denervation, a potential deadly decision in the ED, GLP-1 agonists, and an AHA preview are the topics John Mandrola, MD, discusses in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Renal Denervation
FDA OKs Paradise Renal Denervation System for Hypertension
https://www.medscape.com/viewarticle/998237
- Company Press Release https://www.recormedical.com/recor-medical-and-otsuka-medical-devices-announce-first-fda-approved-renal-denervation-system-for-the-treatment-of-hypertension/
- Six-month Meta-analysis of RDN Studies https://www.ahajournals.org/doi/abs/10.1161/CIRCULATIONAHA.123.066941
- March This Week in Cardiology with RDN Discussion https://www.medscape.com/viewarticle/989014
II. Potential Deadly Decisions in the ED
Even One Night in the ED Raises Risk for Death
https://www.medscape.com/viewarticle/998080
- JAMA Internal Medicine Study
III. Tirzepatide Approval
FDA Approves Tirzepatide for Treating Obesity
https://www.medscape.com/viewarticle/998225
- SURMOUNT 2 https://doi.org/10.1016/S0140-6736(23)01200-X
- SURMOUNT 1 https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
IV. AHA Preview
Mandrola's Top Trials to Look for at AHA 2023
https://www.medscape.com/viewarticle/998123
You may also like:
Medscape editor-in-chief Eric Topol, MD, and master storyteller and clinician Abraham Verghese, MD, on Medicine and the Machine
https://www.medscape.com/features/public/machine
The Bob Harrington Show with Stanford University Chair of Medicine, Robert A. Harrington, MD.
https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact [email protected]
- Visa fler
